查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1467741

2024-2032 年按药物类型、癌症类型、配销通路和地区分類的肿瘤生物相似药市场报告

Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球肿瘤生物相似药市场规模达47亿美元。

癌症是一种生活方式疾病，由于细胞异常生长而发生，并可能导致肿瘤的形成。目前，大多数有效的癌症治疗都是基于生物药物，也称为生物製剂，包括标靶治疗和免疫疗法。这些药物是利用活体生物体（包括细菌、酵母和动物或植物细胞）生产的，需要复杂的製造过程和较长的开发时间。因此，这些药物的成本相对较高，从而增加了癌症治疗的费用。为了降低治疗价格，人们对开髮品牌肿瘤生物製剂的生物相似药的兴趣不断增加。这些生物相似药在有效性和安全性方面与参考生物製剂高度相似，并且由于成本较低，可以帮助显着减少癌症治疗的支出。

多年来，老年人口数量的增加和环境恶化增加了全球癌症的盛行率。这些因素，加上癌症治疗成本的不断上涨，增加了全球医疗保健系统的负担。因此，许多国家的管理当局正在促进生物相似药的采用，作为成本控制措施。例如，美国食品和药物管理局 (USFDA) 为医生和患者开发了资讯材料，以对他们进行生物相似药的教育。除此之外，负担得起的药物的可用性也与更早和更广泛的治疗使用以及改善患者的可及性有关。除此之外，肿瘤生物相似药还可以增加产业竞争，因此有可能进一步压低生物药的价格。其他一些促进市场成长的因素包括品牌生物製剂专利即将到期以及生物相似药製造商增加研发 (R&D) 活动。

本报告回答的关键问题：

  • 迄今为止，全球肿瘤生物相似药市场表现如何，未来几年将如何表现？
  • COVID-19 对全球肿瘤生物相似药产业有何影响？
  • 全球肿瘤生物相似药产业的主要区域市场有哪些？
  • 根据药物类型分類的市场是怎么样的？
  • 根据癌症类型分類的市场是怎么样的？
  • 基于配销通路的市场区隔是什么？
  • 全球肿瘤生物相似药产业价值链的各个阶段是什么？
  • 全球肿瘤生物相似药产业的关键驱动因素和挑战是什么？
  • 全球肿瘤生物相似药产业的结构如何？
  • 全球肿瘤生物相似药产业的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肿瘤生物相似药市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场区隔：依药物类型
  • 市场区隔：按癌症类型
  • 市场区隔：按配销通路
  • 市场区隔：按地区
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 单株抗体
    • 市场走向
    • 市场预测
  • 免疫调节剂
    • 市场走向
    • 市场预测
  • 粒细胞集落刺激因子
    • 市场走向
    • 市场预测
  • 造血剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按癌症类型

  • 肺癌
    • 市场走向
    • 市场预测
  • 大肠直肠癌
    • 市场走向
    • 市场预测
  • 子宫颈癌
    • 市场走向
    • 市场预测
  • 乳癌
    • 市场走向
    • 市场预测
  • 肾癌
    • 市场走向
    • 市场预测
  • 胃癌
    • 市场走向
    • 市场预测
  • 脑癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 欧洲
    • 市场走向
    • 市场预测
  • 亚太地区
    • 市场走向
    • 市场预测
  • 北美洲
    • 市场走向
    • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场预测
  • 拉丁美洲
    • 市场走向
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Biocon Limited
    • Celltrion Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Intas Pharmaceuticals Ltd.
    • STADA Arzneimittel AG
    • Pfizer Inc.
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • BIOCAD Biotechnology Company
    • Mylan NV
    • F. Hoffmann-La Roche AG
Product Code: SR112024A1572

The global oncology biosimilars market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.3 Billion by 2032, exhibiting a growth rate (CAGR) of 22.3% during 2024-2032.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

Monoclonal Antibody

Immunomodulators

G-CSF

Hematopoietic Agents

Others

Breakup by Cancer Type:

Lung Cancer

Colorectal Cancer

Cervical Cancer

Breast Cancer

Kidney Cancer

Stomach Cancer

Brain Cancer

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Others

Breakup by Region:

Europe

Asia Pacific

North America

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology biosimilars industry?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Cancer Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibody
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunomodulators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 G-CSF
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Hematopoietic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Colorectal Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cervical Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Breast Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Stomach Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Brain Cancer
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocon Limited
    • 14.3.2 Celltrion Inc.
    • 14.3.3 Dr. Reddy's Laboratories Ltd.
    • 14.3.4 Intas Pharmaceuticals Ltd.
    • 14.3.5 STADA Arzneimittel AG
    • 14.3.6 Pfizer Inc.
    • 14.3.7 Apotex Inc.
    • 14.3.8 Teva Pharmaceutical Industries Ltd.
    • 14.3.9 Sandoz International GmbH
    • 14.3.10 BIOCAD Biotechnology Company
    • 14.3.11 Mylan N.V.
    • 14.3.12 F. Hoffmann-La Roche AG

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players